- PLATFORM LOGINS
- |
- CONTACT
- Request a Demo
-
GPS CancerTM combines the power of quantitative proteomics with genomics and transcriptomics to understand the "molecular fingerprint" of a cancer patient's tumor enabling personalized treatment options
First cancer test to better inform chemotherapy choice with quantitative measurement of known drug resistance and chemo sensitivity protein biomarkers present in patient's cancer cells
Informed clinical decision support for taxanes, platinum and vinca alkaloids, the backbone of chemotherapy
GPS CancerTM integrates targeted quantitative proteomics with whole genome (DNA) and whole transcriptome (RNA) sequencing, and a knowledge database containing hundreds of oncogenes and approximately 1,500 cellular pathways to identify genomic and proteomic alterations—from DNA to RNA to protein— targeting proteins with high clinical relevance to each person’s tumor and providing oncologists with a detailed molecular profile of a patient’s cancer to inform personalized treatment strategies.
With the capability to measure at a quantitative level, proteins which have known clinical significance relating to activity or resistance to chemotherapy, monoclonal antibody therapy (mAb), hormonal therapy, small molecule targeted therapy and checkpoint inhibitors, GPS CancerTM is the most comprehensive molecular profiling solution of a patient's tumor tissue. Combined with whole genome and transcriptomic analysis, this test provides informed clinical decision support, arming the physician with insight into the patient’s response and resistance to particular therapeutics before treatment begins. This valuable information is available within 21 days of receipt of the tissue, thus enabling clinical utility.
GPS CancerTM results are available to doctors in an easy-to-read report or accessible through the GPS CancerTM Genome Browser, a mobile application available on smartphones including the BlackBerry Priv. The GPS Cancer Genome Browser is the first app enabling a physician and molecular scientists to browse the patient's whole genome down to a single base pair and provide visual insight into genomic alterations coupled to relevant data about that alteration.
GPS CancerTM testing is conducted in the CLIA-certified and
CAP-accredited laboratory of
"2016 has already been a banner year for
“Moreover, GPS CancerTM is an enabler for facilitating the
goals of the Cancer
MoonShot 2020, the nation's most comprehensive cancer care
initiative with the ambitious goal of creating a cancer vaccine by 2020,
Today, many tests employ limited gene panels of 10-400 genes and a reference genome against which a patient’s tumor DNA is compared to identify alteration. GPS CancerTM sequences the whole genome of 20,000+ genes and 3 billion base pairs and matches against the patient’s normal DNA, providing oncologists with an expansive view of alterations to inform personalized treatment strategies specific for that patient. GPS CancerTM extends from genomics to proteomics not only through analysis of RNA but also provides quantitative proteomics through mass spectrometry to measure the amounts of clinically relevant proteins that are the targets of or essential for various therapeutics. This clinically relevant information helps oncologists to better understand how patients may potentially respond to chemotherapies, targeted therapies, and immunotherapies.
"GPS represents the new standard by which all complex molecular testing
on tumors will be compared, there is no other CAP/CLIA approved genomic
offering that come close to this level of sophistication and clinical
utility." –Leonard Sender, MD, Medical Director of the
“As a community oncologist, I couldn’t be more excited to have GPS
Cancer available for my patients, particularly those with more difficult
cases. I treat my patients like my family, and as such, I want them to
have the best,” says
“Using the
“At Indiana University Health, we aim to identify innovative therapeutic
options for metastatic cancer patients through the use of cutting-edge
precision medicine technologies. GPS Cancer with its combination of
genomic and proteomic profiling has revealed numerous opportunities for
treatment, providing actionable results for the majority of our
patients,” says
The payer community has acknowledged the potential of GPS to improve
outcomes by offering coverage for the test. In
“At Sanford Health, we are dedicated to offering our employees
affordable and accessible high-quality care. Not only is GPS Cancer
testing a novel approach to cancer care, it offers our employees – and
their families – the best possible coverage for receiving improved
cancer treatment options,” said
“As a hospital dedicated to providing the most advanced care, it only
makes sense that we would cover the innovative GPS Cancer Testing for
our employees and their families under our insurance plan,” said
Cautionary Note Concerning Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, among others, statements regarding the capabilities and
anticipated utility of our GPS Cancer, including predicting patient
response and resistance to therapeutics, enabling diagnoses by
physicians and accelerating efforts to bring novel combinations of
therapeutic agents to cancer patients, as well as our contribution to
the Cancer 2020 initiative. Forward-looking statements are subject to
numerous risks and uncertainties that could cause actual results to
differ materially from currently anticipated results. Factors that may
cause future results to differ materially from management’s current
expectations include, among other things, that GPS Cancer may not
perform as anticipated, that sufficient physicians may not adopt GPS
Cancer to assist their diagnoses or that healthcare payers may not
provide reimbursement for GPS Cancer as expected. Our business is
subject to numerous additional risks and uncertainties, including, among
others, risks relating to market acceptance of our products; our ability
to successfully launch new products and applications; competition; our
sales, marketing and distribution capabilities; our planned sales,
marketing, and research and development activities; unanticipated
increases in costs or expenses; and risks associated with international
operations. Information on these and additional risks, uncertainties,
and other information affecting our business and operating results can
be found in our existing and future filings with the
About GPS Cancer™
GPS Cancer™ is a unique, comprehensive test available through
About
View source version on businesswire.com: http://www.businesswire.com/news/home/20160603005214/en/
Press@NantHealth.com
Source: